Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?

Mourad Tighiouart, José L. Jiménez, Marcio A. Diniz +1

In parametric Bayesian designs of early phase cancer clinical trials with drug combinations exploring a discrete set of partially ordered doses, several authors claimed that there…